Eloxx Pharmaceuticals Inc (ELOX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$12.74-1.39%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ELOX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | FY 2002 | FY 2001 | FY 2000 | FY 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||||||||||||
| Revenues | — | 6.4 | 0.0 | — | — | — | — | — | — | — | — | 0.2 | 0.0 | 0.2 | — | 0.1 | — | — | — | — | — | — | — | — | — | — | — |
| Total Revenues | — | 6.4 | 0.0 | — | — | — | — | — | — | — | — | 0.2 | 0.0 | 0.2 | — | 0.1 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||||||||||||||||
| R&D Expenses | — | 3.6 | — | — | — | 14.6 | 26.3 | 20.5 | 16.4 | 9.0 | 5.8 | 3.3 | 2.1 | 2.6 | 3.7 | 2.6 | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income | (6.4) | (2.5) | (17.3) | (34.4) | (66.0) | (33.5) | (50.6) | (47.6) | (20.4) | (9.8) | (6.3) | (9.1) | (4.7) | (5.4) | (7.9) | (4.8) | — | — | — | — | — | — | — | — | — | — | — |
| Earnings from Continuing Operations | |||||||||||||||||||||||||||
| Other Non-Operating Income / Expenses | 0.0 | 0.1 | (0.0) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (6.0) | (3.1) | (17.1) | (36.1) | (66.7) | (34.6) | (50.9) | (47.1) | (21.2) | (9.8) | (6.4) | (9.2) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | (0.6) | (0.7) | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | |||||||||||||||||||||||||||
| Net Income | (6.0) | (3.1) | (17.1) | (36.1) | (66.7) | (34.6) | (50.9) | (47.2) | (21.2) | (9.8) | (6.4) | (9.2) | (6.1) | (5.1) | (7.3) | (13.4) | (5.7) | (4.6) | (3.3) | (3.3) | (3.0) | (3.7) | (2.8) | (3.0) | (2.0) | (3.3) | (1.2) |
| Per Share | |||||||||||||||||||||||||||
| Basic EPS | (0.49) | (9.20) | (72.98) | (16.65) | (38.15) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (0.49) | (9.20) | (72.98) | (16.65) | (38.15) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 12.3 | 0.3 | 0.2 | 2.2 | 1.7 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 12.3 | 0.3 | 0.2 | 2.2 | 1.7 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Supplemental | |||||||||||||||||||||||||||
| EBITDA | — | — | — | — | — | — | — | — | (20.3) | (9.7) | (6.1) | (8.8) | (4.4) | (5.2) | (7.8) | (4.7) | — | — | — | — | — | — | — | — | — | — | — |
| EBIT | (6.4) | (2.5) | (17.3) | (34.4) | (66.0) | (33.5) | (50.6) | (47.6) | (20.4) | (9.8) | (6.3) | (9.1) | (4.7) | (5.4) | (7.9) | (4.8) | — | — | — | — | — | — | — | — | — | — | — |
| Effective Tax Rate | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -0.3% | 3.0% | 6.9% | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.